Target of Rapamycin Signaling in Leukemia and Lymphoma

Abstract

Growth factors and many oncogenes activate the lipid kinase phosphoinositide 3-kinase (PI3K), initiating a signaling cascade that includes the protein kinases AKT and target of rapamycin (TOR). The PI3K/AKT/TOR signaling pathway is a significant contributor to disease in various human cancers, including hematologic malignancies. Here we discuss different strategies to inhibit TOR for the treatment of leukemia, lymphoma, and myeloma. The TOR enzyme exists in two complexes in cells, TORC1 and TORC2. The majority of preclinical and clinical efforts to target TOR have involved using rapamycin and its analogs (rapalogs), which suppress TORC1 only partially and do not acutely inhibit TORC2. A new class of small molecules targeting the ATP-binding site of the TOR kinase, termed active-site TOR inhibitors (asTORi), achieves greater inhibition of both TOR complexes, resulting in broader suppression of the PI3K/AKT/TOR signaling network. Preclinical evidence suggests that asTORi have greater efficacy than rapalogs in Philadelphia chromosome-positive acute lymphoblastic leukemia and in T-cell lymphoma. These agents also show greater tolerability in animal models relative to rapalogs or inhibitors of PI3K. These findings encourage broader evaluation of asTORi efficacy in acute myeloid leukemia, B-cell lymphoma, myeloma, and other blood cancers. Clin Cancer Res; 16(22); 5374-80. ©2010 AACR.

Tratamiento de la leucemia linfoide aguda del adulto: Experiencia de un hospital en la Ciudad de México

“…Otros medicamentos como los anticuerpos monoclonales se han estudiado en aquellos pacientes con marcadores como CD20+ y CD19+ 34 . Más recientemente los inhibidores de la vía mTOR (everolimus) se han vuelto una nueva opción en especial en los pacientes con leucemia linfoide T 35 . A pesar de estos avances alrededor del 60% de los pacientes presentará una recaída dentro de los primeros 2 años de tratamiento siendo el principal sitio la médula ósea contando con bajas tasas de segundas RC y aun una supervivencia pobre (24 semanas en promedio) 36 .…”

Cellular Entry of Human Papillomavirus Type 16 Involves Activation of the Phosphatidylinositol 3-Kinase/Akt/mTOR Pathway and Inhibition of Autophagy

“…3F, lane 7). However, rapamycin, which is known to have little effect on the phosphorylation of 4E-BP1 (46,47), inhibited phosphorylation of 4E-BP1 only at a very high concentration (Fig. 3F, lanes 9 and 10).…”

Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies

“…With increasing knowledge and understanding of the role of the different TORC1 and TORC2 complexes in tumorigenesis, there has been substantial interest and extensive preclinical efforts to develop the next generation of mTOR inhibitors, with dual inhibitory activities against both TORC1 and TORC2 complexes [4,[108][109][110][111][112][113][114][115]. Such efforts are especially relevant with the emerging realization that the first class of inhibitors, the rapalogs, have so far shown significant clinical efficacy only against some relatively rare types of malignancies (RCC, pancreatic neuroendocrine tumors and mantle cell lymphoma), whereas major objective response rates are limited in more common solid tumors [116].…”